MktsMarkets

VYNE Therapeutics Inc.
NASDAQ: VYNEKey statistics
VYNE News
Stories mentioning VYNE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 | Q1 '24Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 86.00 | 178.00 | 69.00 | 202.00 | 84.00 | 121.00 | 198.00 | 98.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 817.00 | (2,016) | 4,881 | 6,124 | 9,684 | 10,248 | 7,306 | 3,708 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (3,816) | 81.00 | (7,542) | (9,197) | (12,770) | (13,091) | (10,396) | (7,380) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 231.00 | (306.00) | 1,795 | 594.00 | 760.00 | 934.00 | 1,001 | 1,139 |
| Pretax Income | (3,585) | (225.00) | (5,747) | (8,603) | (12,010) | (12,157) | (9,395) | (6,241) |
| Tax Provision | 0.00 | 4.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (3,585) | 40.00 | (5,755) | (8,611) | (12,022) | (12,157) | (9,406) | (6,249) |
| Earnings Per Share (Basic) | (0.08) | 0.00 | (0.13) | (0.20) | (0.28) | (0.29) | (0.22) | (0.15) |
| Earnings Per Share (Diluted) | (0.08) | 0.00 | (0.13) | (0.20) | (0.28) | (0.29) | (0.22) | (0.15) |
| Weighted Average Shares Outstanding (Basic) | 42,768 | 42,768 | 42,759 | 42,673 | 42,589 | 42,587 | 42,586 | 42,581 |
| Weighted Average Shares Outstanding (Diluted) | 42,768 | 42,768 | 42,759 | 42,673 | 42,589 | 42,587 | 42,586 | 42,581 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VYNE
VYNE Therapeutics Inc. (NASDAQ: VYNE) is a stock listed on the Nasdaq Stock Market under the ticker symbol VYNE. It last traded at $28.68 (Sep 21, 2026, 8:00 PM ET), up 1.3% on the day. That gives VYNE Therapeutics a market capitalisation of $93.5M.
Over the past 52 weeks VYNE has traded between $16.04 and $46.95.
Revenue for the quarter ended Mar 31, 2026 was $86.0K; a net loss of $3.6M. Revenue was down 57.4% from $202.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $86.0K | -$3.6M | -4168.6% |
| Dec 31, 2025 | $178.0K | $40.0K | 22.5% |
| Jun 30, 2025 | $69.0K | -$5.8M | -8340.6% |
| Mar 31, 2025 | $202.0K | -$8.6M | -4262.9% |
From VYNE Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…